Anti-tuberculosis activity of Rivaroxabane in silico and in vitro

Abstract

The activity of Rivaroxoban of oxazolidinone series against Mycobacterium terrae was investigated in silico and in vitro. In silico studies have shown a high binding affinity of Rivaroxaban to β-ketoacyl[ACP]synthase I that plays a key role in the biosynthesis of mycolic acids, being the components of the mycobacterial cell wall. In the molecular docking study, two main binding sites of Rivaroxaban with protein were predicted and evaluated: the minimum binding energies were found for the both sites with the values of –10.26 kcal/mol and –8.99 kcal/mol. A solution of Rivaroxaban (200 μg/ml) has been shown to inhibit the growth of a Mycobacterium terrae culture. The data obtained open up the prospect of developing new effective anti-tuberculosis drugs of oxazolidinone series.